Akoya BioSciences
AKYA
AKYA was delisted on the 7th of July, 2025.
61 hedge funds and large institutions have $27.8M invested in Akoya BioSciences in 2024 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 8 closing their positions.
2,380% more call options, than puts
Call options by funds: $124K | Put options by funds: $5K
46% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 13
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
3% more funds holding
Funds holding: 59 → 61 (+2)
0.06% more ownership
Funds ownership: 24.43% → 24.49% (+0.06%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
16% less capital invested
Capital invested by funds: $32.9M → $27.8M (-$5.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SW
SVB Wealth
Boston,
Massachusetts
|
+$1.37M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$207K |
| 3 |
BlackRock
New York
|
+$151K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$116K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$105K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$1.02M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$396K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$344K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$206K |
| 5 |
Morgan Stanley
New York
|
-$108K |
AKYA Hedge Fund Activity: Q4 2024 in Review
61 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Akoya BioSciences (AKYA) for Q4 2024, worth a combined $27.8M — down 16% from $32.9M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new AKYA positions and 8 closed out — a net gain of 2 holders — while 19 added to existing stakes and 13 trimmed.
The largest buyer was SVB Wealth, opening a new position worth an estimated $1.37M. The largest seller was Parkman Healthcare Partners, exiting entirely with an estimated $1.02M sold.
- 61 institutional investors held Akoya BioSciences (AKYA) as of Q4 2024, up from 59 in Q3 2024.
- Funds reported $27.8M of Akoya BioSciences stock for Q4 2024, down 16% quarter-over-quarter.
- 10 funds opened new Akoya BioSciences positions in Q4 2024 and 8 closed out, a net change of +2 holders.
- The largest Akoya BioSciences buyer in Q4 2024 was SVB Wealth, an estimated $1.37M added.
- The largest Akoya BioSciences seller in Q4 2024 was Parkman Healthcare Partners, an estimated $1.02M sold.
Based on aggregated 13F filings for Q4 2024.